Related Experiment Video

Updated: Jan 6, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.7K

MicroRNA-1271 inhibits the progression of papillary thyroid carcinoma by targeting IRS1 and inactivating AKT pathway

Y Chen1, S-A Hao, Y Jiang

  • 1Department of Breast, Thyroid Surgery, Research Institute of Surgery, Daping Hospital, Army Military Medical University, Chongqing, China. luodl968@163.com.

European Review for Medical and Pharmacological Sciences
|October 11, 2019
PubMed
Abstract

Insights

MicroRNA-1271 (miR-1271) suppresses papillary thyroid carcinoma (PTC) progression by targeting insulin receptor substrate 1 (IRS1). This inhibition blocks epithelial-mesenchymal transition (EMT) and the AKT pathway, offering therapeutic potential for PTC.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • MicroRNA-1271 (miR-1271) is implicated in various human diseases and cancers.
  • The specific role of miR-1271 in papillary thyroid carcinoma (PTC) requires clarification.

Purpose of the Study:

  • To investigate the biological function and mechanism of miR-1271 in papillary thyroid carcinoma (PTC).

Main Methods:

  • Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) and Western blot were used to measure gene and protein expression.
  • Methyl thiazolyl tetrazolium (MTT) and transwell assays assessed cell proliferation, migration, and invasion.
  • Dual-Luciferase assay confirmed the direct targeting relationship between miR-1271 and insulin receptor substrate 1 (IRS1).

Main Results:

  • MiR-1271 expression was significantly downregulated in PTC tissues.
  • Overexpression of miR-1271 suppressed PTC cell proliferation, migration, and invasion.
  • Insulin receptor substrate 1 (IRS1) was identified as a direct target of miR-1271; IRS1 knockdown mimicked miR-1271's suppressive effects.
  • MiR-1271 was found to inhibit PTC progression by targeting IRS1, consequently blocking the epithelial-mesenchymal transition (EMT) and the protein kinase B (AKT) pathway.

Conclusions:

  • MiR-1271 acts as a tumor suppressor in PTC.
  • The mechanism involves targeting IRS1, thereby inhibiting EMT and the AKT pathway.
  • MiR-1271 represents a potential therapeutic target for papillary thyroid carcinoma.

More Related Videos

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

18.0K
An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

8.8K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.7K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K